Drug Trial Radar · NCT07928570
A Clinical Study of MHB034C for Injection in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Dec 20, 2026
Primary completion
Jun 15, 2028
Study completion May 19, 2029
Sponsor
- Lead sponsor
- Minghui Pharmaceutical (Shanghai) LTDIndustry
- Sponsor type
- Industry
- First posted
- Nov 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, multicenter, first-in-human (FIH) Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of MHB034C in participants with advanced solid tumors.
Conditions
- Advanced Malignant Solid Tumor
Interventions
MHB034C for InjectionDrug
MHB034C for Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I Dose Escalation Stage: Incidence of DLTTime frame: At the end of Cycle 1 (each cycle is 21 days for Q3W administration and 28 days for Q2W administration)
- Phase I Dose Escalation Stage: Incidence of Adverse events (AEs)Time frame: from Day1 to 30 days after last dose
- Phase I Dose Escalation Stage: Incidence of Serious adverse events (SAEs)Time frame: from Day1 to 30 days after last dose
- Phase I Dose Escalation Stage: MTDTime frame: At the end of Cycle 1 (each cycle is 21 days for Q3W administration and 28 days for Q2W administration)
- Phase I Dose Escalation Stage: RP2DTime frame: from Day1 to 30 days after last dose
- Phase II Dose Expansion Stage: ORR as assessed by the investigator per RECIST v1.1.Time frame: One year after the last subject was enrolled in the group
- Phase II Dose Expansion Stage: DCR as assessed by the investigator per RECIST v1.1.Time frame: One year after the last subject was enrolled in the group
- Phase II Dose Expansion Stage: DoR as assessed by the investigator per RECIST v1.1.Time frame: One year after the last subject was enrolled in the group
- Phase II Dose Expansion Stage: PFS as assessed by the investigator per RECIST v1.1.Time frame: One year after the last subject was enrolled in the group
- Phase II Dose Expansion Stage: OS as assessed by the investigator per RECIST v1.1.Time frame: One year after the last subject was enrolled in the group
- Phase II Dose Expansion Stage: PFS rates at 6 and 12 months.Time frame: One year after the last subject was enrolled in the group
- Phase II Dose Expansion Stage: OS rates at 6 and 12 months.Time frame: One year after the last subject was enrolled in the group
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.